Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LAB CVE:MKT NASDAQ:PRE NYSE:SENS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLABStandard BioTools$1.29+4.0%$1.30$0.92▼$2.32$481.31M1.291.10 million shs1.54 million shsMKTDeepMarkitC$0.09+12.5%C$0.07C$0.04▼C$0.11C$1.11M-1.24445945,836 shs147,308 shsPREPrenetics Global$8.10-0.6%$7.92$3.09▼$11.99$98.88M0.1530,638 shs22,635 shsSENSSenseonics$0.45-0.2%$0.49$0.25▼$1.40$368.24M0.937.98 million shs9.06 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLABStandard BioTools+4.03%+0.78%-2.27%+30.30%-34.85%MKTDeepMarkit+12.50%+38.46%+38.46%+100.00%+38.46%PREPrenetics Global-0.61%+9.46%+3.58%-1.34%+65.31%SENSSenseonics-0.22%-2.84%-10.99%-14.44%+20.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLABStandard BioTools1.9755 of 5 stars2.02.00.00.02.74.20.6MKTDeepMarkitN/AN/AN/AN/AN/AN/AN/AN/APREPrenetics Global1.5412 of 5 stars2.53.00.00.01.50.01.3SENSSenseonics1.9408 of 5 stars3.71.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLABStandard BioTools 2.00Hold$1.5520.16% UpsideMKTDeepMarkit 0.00N/AN/AN/APREPrenetics Global 3.00Buy$9.0011.11% UpsideSENSSenseonics 3.40Buy$1.54240.15% UpsideCurrent Analyst Ratings BreakdownLatest MKT, LAB, PRE, and SENS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025SENSSenseonicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$1.508/27/2025SENSSenseonicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$1.508/13/2025LABStandard BioToolsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold8/13/2025LABStandard BioToolsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$1.557/17/2025LABStandard BioToolsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/17/2025SENSSenseonicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/15/2025SENSSenseonicsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.257/8/2025SENSSenseonicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$1.10 ➝ $1.40(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLABStandard BioTools$174.43M2.83N/AN/A$1.11 per share1.16MKTDeepMarkitN/AN/AC$0.02 per share5.00C($0.03) per shareN/APREPrenetics Global$30.62M3.43N/AN/A$13.20 per share0.61SENSSenseonics$25.47M14.46N/AN/A$0.07 per share6.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLABStandard BioTools-$138.88M-$0.32N/AN/AN/A-69.08%-20.23%-15.32%10/29/2025 (Estimated)MKTDeepMarkit-C$6.31M-C$0.02N/A∞N/AN/A-295.34%-190.23%N/APREPrenetics Global-$46.30M-$3.99N/AN/AN/A-115.91%-28.07%-22.27%10/6/2025 (Estimated)SENSSenseonics-$60.39M-$0.10N/AN/AN/A-362.30%-842.25%-67.99%N/ALatest MKT, LAB, PRE, and SENS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q1 2025PREPrenetics GlobalN/A-$0.80N/A-$0.80N/A$17.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLABStandard BioToolsN/AN/AN/AN/AN/AMKTDeepMarkitN/A3.57%N/AN/AN/APREPrenetics GlobalN/AN/AN/AN/AN/ASENSSenseonicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLABStandard BioToolsN/A5.164.92MKTDeepMarkit0.820.354.68PREPrenetics GlobalN/A2.071.89SENSSenseonics59.172.472.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLABStandard BioTools53.74%MKTDeepMarkit10.24%PREPrenetics Global25.01%SENSSenseonics12.36%Insider OwnershipCompanyInsider OwnershipLABStandard BioTools23.16%MKTDeepMarkit8.42%PREPrenetics GlobalN/ASENSSenseonics3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLABStandard BioTools620381.99 million293.53 millionOptionableMKTDeepMarkit6,40012.35 millionN/ANot OptionablePREPrenetics Global112.98 millionN/ANot OptionableSENSSenseonics90814.68 million573.90 millionN/AMKT, LAB, PRE, and SENS HeadlinesRecent News About These CompaniesSenseonics signs MOU with Ascensia Diabetes Care2 hours ago | msn.comSenseonics to take over commercial efforts for Eversense 365 from Ascensia2 hours ago | drugdeliverybusiness.comDAscensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner SenseonicsSeptember 3 at 7:22 PM | businesswire.comSenseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365September 3 at 5:17 PM | globenewswire.comSenseonics Holdings, Inc. (NYSE:SENS) Given Average Recommendation of "Buy" by BrokeragesSeptember 1 at 2:47 AM | americanbankingnews.comSenseonics (NYSE:SENS) Upgraded by Barclays to Strong-Buy RatingAugust 31, 2025 | marketbeat.comBarclays Initiates Coverage on Senseonics (NYSE:SENS)August 30, 2025 | americanbankingnews.comSenseonics Holdings, Inc. (NYSE:SENS) Receives Consensus Recommendation of "Buy" from AnalystsAugust 29, 2025 | marketbeat.comHere's Why Senseonics (SENS) Is a Great 'Buy the Bottom' Stock NowAugust 21, 2025 | zacks.comInformed Momentum Co LLC Acquires Shares of 852,215 Senseonics Holdings, Inc. (NYSE:SENS)August 14, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Senseonics Q4 Earnings?August 12, 2025 | marketbeat.comSenseonics Holdings, Inc. (SENS) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSenseonics posts Street-beating Q2 with 37% sales growthAugust 6, 2025 | drugdeliverybusiness.comDSenseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue EstimatesAugust 6, 2025 | zacks.comSenseonics Holdings, Inc. Reports Second Quarter Financial ResultsAugust 6, 2025 | globenewswire.comSenseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call ...July 16, 2025 | gurufocus.comSenseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern TimeJuly 16, 2025 | globenewswire.comSequel Med Tech expects full twiist launch in the fallJuly 15, 2025 | drugdeliverybusiness.comDNew glucose sensors, insulin patch pumps lead ADA’s Scientific SessionsJuly 3, 2025 | medtechdive.comMADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensorsJune 24, 2025 | medtechdive.comMSenseonics lays out hopes for next-gen CGM commercial timelinesJune 24, 2025 | drugdeliverybusiness.comDNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Rocket Lab Scores Analyst Upgrades, Finalizes Geost TakeoverBy Ryan Hasson | August 13, 2025CrowdStrike Stock Slides—Is Growth Momentum Tapping Out?By Chris Markoch | August 7, 2025Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?By Ryan Hasson | August 9, 2025MKT, LAB, PRE, and SENS Company DescriptionsStandard BioTools NASDAQ:LAB$1.29 +0.05 (+4.03%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.28 -0.01 (-0.78%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.DeepMarkit CVE:MKTC$0.09 +0.01 (+12.50%) As of 09/3/2025 05:40 PM EasternDeepMarkit Corp. provides game-based marketing software services. The company operates DeepMarkit platform and MintCarbon.io platform, a web-based software-as-a-service platform that facilitates the minting of carbon credits into non-fungible tokens. The company was formerly known as Challenger Deep Resources Corp. and changed its name to DeepMarkit Corp. in October 2015. DeepMarkit Corp. was incorporated in 2007 and is headquartered in Calgary, Canada.Prenetics Global NASDAQ:PRE$8.10 -0.05 (-0.61%) Closing price 09/3/2025 03:59 PM EasternExtended Trading$8.19 +0.09 (+1.11%) As of 09/3/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.Senseonics NYSE:SENS$0.45 0.00 (-0.22%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$0.54 +0.09 (+19.03%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
